Browse Articles

Discover research articles across all indexed journals

Influence of homogenization and pasteurization on the physical characteristics, antioxidant properties, and microbial content of VD20 rice milk

Scientific Reports Ngoc Kim Giang Tu, Thi Kim Loan Le, Thi Yen Nhi Tran et al. Mar 20, 2025 DOI: 10.1038/s41598-025-88436-z

Abstract The preservation and stability of rice milk products are critical for their commercialization. This study focuses on the effects of homogenization and pasteurization on the stability and microbial safety of rice milk produced from VD20 broken rice, a variety cultivated in Go Cong, Tien Giang, Vietnam. Experiments were conducted by homogenizing the rice milk at four rotational speeds (6000, 8000, 10,000, and 12,000 rpm) for varying durations (5, 10, 15, and 20 min) and pasteurizing temperatures ranging from 80 °C to 95 °C. Homogenization was performed using an IKA T50 ULTRA-TURRAX® homogenizer, and microbial counts were determined using standard plate count methods. The optimal processing conditions were identified as homogenization at 10,000 rpm for 15 min and pasteurization at 90 °C for 15 min, which ensured microbial safety (< 10⁵ CFU/mL) while preserving antioxidant activity (DPPH: 42.35 mgAAE/mL, ABTS: 39.01 mgAAE/mL) and polyphenol content (TPC: 78.55 mgGAE/mL). These findings contribute to optimizing the production and extending the shelf life of rice milk products, thereby enhancing the value of broken rice by-products and supporting the diversification of rice-derived functional beverages.

Toward real-time margin assessment in breast-conserving surgery with hyperspectral imaging

Scientific Reports Lynn-Jade S. Jong, Dinusha Veluponnar, Freija Geldof et al. Mar 20, 2025 DOI: 10.1038/s41598-025-94526-9

Dense-Fusion2Net a more efficient and lightweight short speech speaker recognition system with time-frequency channel attention

Scientific Reports Fei Deng, Rui Huang, Peifan Jiang et al. Mar 20, 2025 DOI: 10.1038/s41598-025-93873-x

A new method for Tomicus classification of forest pests based on improved ResNet50 algorithm

Scientific Reports Caiyi Li, Quanyuan Xu, Ying Lu et al. Mar 20, 2025 DOI: 10.1038/s41598-025-93407-5

A PDMS/MWCNTs RFID flexible tag with advanced resonator design for read range enhancement in IoT monitoring systems

Scientific Reports Hafsa Anam, Syed Muzahir Abbas, Iain B. Collings et al. Mar 20, 2025 DOI: 10.1038/s41598-025-86773-7

Abstract Low-cost and passive identification systems are necessary for real time IoT (internet of things) monitoring. The paper presents a novel designed chipless RFID tag towards read range enhancement of (2.70 mm). A novel approach of array-based resonators towards real time read range enhancement is proposed in this research work with efficient performance. A mould-based solution casting technique is used for chipless tag fabrication. Multi-Walled Carbon Nanotubes (MWCNTs) are used as electrodes with flexible Polydimethylsiloxane (PDMS) substrate. The developed battery-free tag can encode 3-bits data while staying in compact dimensions of 20 × 20mm2. The single unit tag is extended to 3 × 3-array structure. The novel approach leads the tag towards RCS increment of 25.17dBsm. The tag has been extended to 5 × 5-array for Poly-ethylene terephthalate (PET) substrate with silver nanoparticle-based ink radiator leading to RCS increment of 25.16dBsm. The tags read range performance is very highly reliable and stable as measured from multiple samples and is suitable for deployment in a smart sensing and IoT identification network.

Author Correction: Vitality insights of fish escaping from a sorting grid installed on a bottom trawl net

Scientific Reports Andrea Petetta, Bent Herrmann, Daniel Li Veli et al. Mar 20, 2025 DOI: 10.1038/s41598-025-94407-1

BMAL1 attenuates intervertebral disc degeneration by activating the SIRT1/PGC-1α pathway: evidence from vitro studies

Scientific Reports Peiming Sang, Yanyan Ma, Xie Zhang et al. Mar 20, 2025 DOI: 10.1038/s41598-025-94029-7

Treatment of IL-10RA deficiency of pediatric patients with very early onset inflammatory bowel disease by allogeneic haematopoietic stem cell transplantation

Scientific Reports Yafeng Wang, Dandan Liu, Haili Gao et al. Mar 20, 2025 DOI: 10.1038/s41598-025-92979-6

Surface motion dynamics and swimming control of planar magnetic microswimmers

Scientific Reports Yasin Cagatay Duygu, Sangwon Lee, Austin Liu et al. Mar 20, 2025 DOI: 10.1038/s41598-025-94078-y

Abstract Planar magnetic microswimmers offer substantial potential for in vivo biomedical applications, owing to their efficient mass production via photolithography. In this study, we demonstrate the effective control of these microswimmers using an open-loop approach in environments with minimal external disturbances. We investigate their surface motion characteristics through both theoretical modeling and experimental testing under varying magnetic field strengths and rotation frequencies, identifying regions of stable and unstable motion. Additionally, we analyze how field frequency and strength influence surface motion speed and identify the frequencies that promote stability. Open-loop control of surface motion in fluid environments and swimming in channels is also demonstrated, highlighting the operational flexibility of these microswimmers. We further demonstrate swarm motion for both swimming and surface operations, exhibiting larger-scale coordination. Our findings emphasize their potential for future applications in biomedical engineering and microrobotics, marking a step forward in the development of microscale robotic systems.

Comparative analysis of perinatal outcomes in pregnant women with pregestational diabetes mellitus based on diagnostic timing

Scientific Reports Xinyu Shu, Juan Juan, Xin Kang et al. Mar 20, 2025 DOI: 10.1038/s41598-025-93449-9

A single-phase seven-level ANPC inverter with hybrid modulation for enhanced efficiency and harmonic performance

Scientific Reports Bisma Saif, Adil Sarwar, Mohammad Zaid et al. Mar 20, 2025 DOI: 10.1038/s41598-025-93660-8

High proportions of multidrug-resistant Klebsiella pneumoniae isolates in community-acquired infections, Brazil

Scientific Reports Adriano de Souza Santos Monteiro, Márcio de Oliveira Silva, Vívian Santos Galvão et al. Mar 20, 2025 DOI: 10.1038/s41598-025-92549-w

Abstract Klebsiella pneumoniae is one of the leading causes of bloodstream (BSI) and urinary tract infections (UTI), but limited data is available regarding community-acquired (CA) infections. This study characterized the clinical aspects of CA-BSI and CA-UTI caused by K. pneumoniae and the molecular features of isolates, including their resistance profiles. Sixty-five isolates (CA-BSI, n = 24; CA-UTI, n = 41) underwent antimicrobial susceptibility testing, β-lactamase and virulence gene assessment, capsular genotyping, and molecular typing. Older age, male gender, and comorbidities, particularly kidney disease, were significantly associated with CA-BSI. The MDR and carbapenem resistance rates for K. pneumoniae from CA infections were 24.6% and 4.6%, respectively. CA-BSI isolates were more antibiotic-resistant and had a higher proportion of ESBL-producing (37.5% versus 9.8%) and MDR isolates (45.8% versus 12.2%) than CA-UTI. The bla CTX−M−like or bla KPC−like genes was found in all ESBL-producing isolates, while bla KPC−like and bla NDM−like were detected exclusively in CA-BSI strains. The isolates’ virulence profiles were similar between the groups, although one CA-BSI and two CA-UTI isolates presented hypervirulence biomarkers. A high clonal diversity was observed, with a majority of MDR (81.3%) (ST11, ST15, ST101, ST258, ST307, and ST6852) and hypervirulent (2/3) (ST23 and ST65) isolates being high-risk pandemic clones in humans. Our data highlight the high prevalence of MDR K. pneumoniae in CA infections in Brazil, with CA-BSI showing significant differences in resistance profiles compared to CA-UTI.

Paracancerous binuclear hepatocytes assessed by computer program is a novel biomarker for short term recurrence of hepatocellular carcinoma after surgery

Scientific Reports Yifan Zhang, Yiquan Lu, Nan Wang et al. Mar 20, 2025 DOI: 10.1038/s41598-025-90004-4

Adjuvant Chemotherapy on Resected Intraductal Papillary Mucinous Neoplasm–Derived Pancreatic Cancer: Addressing Statistical and Methodological Concerns in Survival Analysis

Journal of Clinical Oncology Guang Xiong Mar 20, 2025 DOI: 10.1200/jco-24-02054

A novel foldable metamaterial for application in the pipeline pressure vessel with a static deformation, strain and stress analysis

Scientific Reports Xu Ying, An Yunzhu, Ye Qige et al. Mar 20, 2025 DOI: 10.1038/s41598-025-93302-z

Long-Term Follow-Up and Overall Survival in NRG258, a Randomized Phase III Trial of Chemoradiation Versus Chemotherapy for Locally Advanced Endometrial Carcinoma

Journal of Clinical Oncology Daniela E. Matei, Danielle M. Enserro, Marcus E. Randall et al. Mar 20, 2025 DOI: 10.1200/jco.24.01121

This randomized phase III trial aimed to determine whether treatment with cisplatin and volume-directed radiation followed by carboplatin and paclitaxel for four cycles (chemoradiotherapy [C-RT]) increased recurrence-free survival (RFS) and overall survival (OS) when compared with carboplatin and paclitaxel for six cycles (chemotherapy [CT]) in locally advanced endometrial cancer (UC). Previously reported results showed that C-RT did not improve RFS compared with CT. Here we report the final OS analysis. Patients with International Federation of Gynecology and Obstetrics (FIGO) 2009 stage III-IVA UC or stage I/II serous or clear cell UC and positive cytology were enrolled. The primary objective was RFS. Secondary objectives were OS, toxicity, and quality of life. Cumulative probabilities of OS were estimated using the Kaplan-Meier method. Subgroup analyses of treatment effect for FIGO stage, age, race, gross residual disease, histology, lymph-vascular space invasion, and body mass index were performed. In total, 813 patients were randomly assigned (407 C-RT and 406 CT). The median follow-up was 112 months. Median OS was not achieved in either arm. The stratified hazard ratio for death comparing C-RT versus CT was 1.05 (95% CI, 0.82 to 1.34, log-rank two-sided P value = .72). None of the factors analyzed predicted OS benefit from C-RT. Although C-RT reduced the rate of local recurrence compared with CT, it did not increase OS or RFS in stage III/IVA UC.

Willingness of healthcare professionals in China to continue participating in and recommend telemedicine post COVID-19 pandemic

Scientific Reports Weiyi Wang, Xianying He, Xu Zhang et al. Mar 20, 2025 DOI: 10.1038/s41598-025-93801-z

Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Recurrent Small Hepatocellular Carcinoma: A Randomized, Open-Label, Controlled Trial

Journal of Clinical Oncology Mian Xi, Zhoutian Yang, Li Hu et al. Mar 20, 2025 DOI: 10.1200/jco-24-01532

PURPOSE To assess the efficacy and safety of radiofrequency ablation (RFA) versus stereotactic body radiotherapy (SBRT) in treating recurrent small hepatocellular carcinoma (HCC). METHODS In this trial, patients with recurrent small HCC (single lesion ≤5 cm) were randomly assigned to receive either SBRT or RFA. The primary end point was local progression-free survival (LPFS), and secondary end points were progression-free survival (PFS), overall survival (OS), local control rate, and safety. RESULTS Between August 2019 and April 2022, 166 patients were assigned to SBRT (n = 83) and RFA (n = 83) groups. After a median follow-up time of 42.8 and 42.9 months in the SBRT and RFA groups, respectively, SBRT demonstrated a significantly better LPFS than that of RFA (hazard ratio [HR], 0.45 [95% CI, 0.24 to 0.87]; P = .014). The 2-year LPFS rates were 92.7% (95% CI, 87.3 to 98.5) with SBRT and 75.8% (95% CI, 67.2 to 85.7) with RFA. The median PFS time of the SBRT and RFA groups was 37.6 (95% CI, 26.0 to 49.2) and 27.6 (95% CI, 20.3 to 34.8) months, respectively (HR, 0.76 [95% CI, 0.50 to 1.15]; P = .190). Nine patients in the SBRT group and 10 in the RFA group died during the follow-up. The 2-year OS rates were 97.6% (95% CI, 94.3 to 100.0) in the SBRT group and 93.9% (95% CI, 88.9 to 99.2) in the RFA group (HR, 0.91 [95% CI, 0.37 to 2.22]; P = .830). The incidences of both acute and late adverse events were comparable between the groups ( P = .436 and P = .715, respectively). CONCLUSION SBRT achieved better LPFS than that of RFA in patients with single recurrent HCC ≤5 cm, especially in HCC ≤2 cm, whereas PFS, OS, and safety were comparable between the two treatments.

Efficient uremic toxins adsorption from simulated blood by immobilization of metal organic frameworks anchored Sephadex beads

Scientific Reports Reda M. Abdelhameed, Mahmoud El-Shahat, Bahira Hegazi et al. Mar 20, 2025 DOI: 10.1038/s41598-025-92492-w

Abstract The current study outlines the removal of Creatinine, p-Cresol sulfate, and Hippuric acid from simulated blood using three new granules: Fe-BTC@Sephadex, Cu-BTC@Sephadex, and Co-BTC@Sephadex. Beads were used to adsorbed toxic chemicals, and the effects of various experimental parameters were examined in the adsorption optimization process. The framework’s adsorption isotherms were explained by the application of the Freundlich and Langmuir models. The kinetics of adsorption is represented by a pseudo-first and second-order equation. The morphology and structure of the Fe-BTC@ Sephadex, Co-BTC@ Sephadex, and Cu-BTC@Sephadex beads were investigated using Fourier transform infrared spectroscopy (FT-IR), scanning electron microscopy (SEM), and X-ray diffraction (XRD). The adsorption capacities for creatinine were 545.69, 339.76, and 189.88 mg/g for Fe-BTC@ Sephadex, Cu-BTC@ Sephadex, and Co-BTC@ Sephadex, respectively, according to the results; the corresponding adsorption capacities for hippuric acid were 323.78, 206.79, and 68.059 mg/g, and the maximum adsorption capacities for p-Cresol sulfate were 122.65, 71.268, and 40.347 mg/g, respectively. These were, in fact, promising findings that have implications for an industrial-scale transportable artificial kidney.

Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II Study

Journal of Clinical Oncology Shailender Bhatia, Suzanne L. Topalian, William Sharfman et al. Mar 20, 2025 DOI: 10.1200/jco-24-02138

PURPOSE Approximately 50% of patients with advanced Merkel cell carcinoma (MCC) have primary or acquired resistance to PD-(L)1 blockade, which may be overcome using combination immune checkpoint inhibition (ICI) with anti–cytotoxic T lymphocyte antigen-4 antibody. We present results from the recurrent/metastatic MCC cohort in CheckMate 358, a nonrandomized, multicohort, phase I/II study of nivolumab (NIVO) with or without ipilimumab (IPI) in virus-associated cancers (ClinicalTrials.gov identifier: NCT02488759 ). METHODS ICI-naïve patients with recurrent/metastatic MCC and 0-2 previous systemic therapies were administered NIVO monotherapy at 240 mg once every 2 weeks or combination therapy with NIVO 3 mg/kg once every 2 weeks + IPI 1 mg/kg once every 6 weeks. The primary end point was objective response. Secondary end points included duration of response (DOR), progression-free survival (PFS), and overall survival (OS). RESULTS Sixty-eight patients received NIVO (n = 25) or NIVO + IPI (n = 43). The objective response rate (95% CI) and median DOR (95% CI), respectively, were 60% (38.7 to 78.9) and 60.6 months (16.7 to not applicable [NA]) with NIVO and 58% (42.1 to 73) and 25.9 months (10.4 to NA) with NIVO + IPI. The median PFS (95% CI) and OS (95% CI), respectively, were 21.3 (9.2 to 62.5) and 80.7 (23.3 to NA) months with NIVO and 8.4 (3.7 to 24.3) and 29.8 (8.5 to 48.3) months with NIVO + IPI. The incidence of grade 3/4 treatment-related adverse events was 28% with NIVO and 47% with the combination. CONCLUSION This nonrandomized study showed frequent and durable responses with both NIVO and NIVO + IPI in patients with ICI-naïve advanced MCC. However, it did not show improvement in efficacy with the combination, thus contradicting previous study reports that had suggested clinical benefit with combination ICI. A randomized trial of NIVO + IPI versus NIVO monotherapy is warranted.